DI
CGTX icon

Diligent Investors’s Cognition Therapeutics CGTX Stock Holding History

Diligent Investors’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,000
Closed -$19.8K – 292
2023
Q1 		$19.8K Sell
10,000
-10,000
-50% -$19.1K 0.01% 285
2022
Q4 		$42K Sell
20,000
-10,520
-34% -$21.2K 0.01% 280
2022
Q3 		$58K Hold
30,520
– – 0.02% 254
2022
Q2 		$64K Hold
30,520
– – 0.02% 255
2022
Q1 		$84K Buy
+30,520
New +$118K 0.02% 270

Other funds holding CGTX

PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
PWM
Perigon Wealth Management San Francisco, California $5.51B AUM 24.51% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Diligent Investors's CGTX Position: Q2 2023 in Review

Diligent Investors sold out of Cognition Therapeutics (CGTX) in Q2 2023, closing a stake of 10,000 shares — an estimated $19.8K sold.

Diligent Investors first reported a position in CGTX in Q1 2022 and held it in 5 quarters. The position peaked at $84K in Q1 2022. 35 funds tracked by Wall St. Rank hold CGTX as of Q2 2023.

  • Diligent Investors reported no remaining Cognition Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Diligent Investors sold 10,000 Cognition Therapeutics shares in Q2 2023, an estimated $19.8K.
  • Diligent Investors first reported a position in Cognition Therapeutics in Q1 2022 and held it in 5 quarters.
  • Diligent Investors's Cognition Therapeutics position peaked at $84K in Q1 2022.
  • 35 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2023.

Based on Diligent Investors's 13F filing for Q2 2023, filed 24 Jul 2023.